Genentech recently released positive results for its Phase III ALEX study analyzing Alecensa, a drug that treats anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Read More »
Sanofi and Regeneron Pharmaceuticals recently announced positive results from two Praluent-focused Phase 3b/4 Odyssey-DM trials involving diabetes patients. Read More »
Genentech, a member of the Roche Group, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently announced positive results from the Phase III Aphinity study for Perjeta and Herceptin-based adjuvant treatment in combating breast cancer. Read More »
Generic drug makers insist they attempted to work with state legislators in Maryland to carve out a bill to curb "price gouging," but they ignored the advice and passed an unconstitutional law, according to an industry group. Read More »
Pharmaceutical Care Management Association (PCMA) recently announced that it has initiated litigation proceedings in federal court in response to a pair of state laws which it believes jeopardizes patient safety and concurrently increases prescription costs. Read More »
eFFECTOR Therapeutics recently presented Phase 1 clinical trial data for its lead product candidate, eFT508, at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Read More »
Endo International plc has voluntarily opted to withdraw its Opana ER (oxymorphone hydrochloride extended release) product from the market after an FDA request in June, following a thorough review period and collaboration with the agency. Read More »
McKesson Pharmacy Systems recently unveiled two new features — Medication Synchronization and Mobile Delivery — serving its pharmacy management suite, which comprises EnterpriseRx, PharmacyRx and Pharmaserv systems. Read More »
Texas-based Maxor National Pharmacy Services LLC recently unveiled two on-site pharmacy shops for Unity Health Care's Parkside and Upper Cardozo Health Centers, both with physical locations serving the community in Washington, D.C. Read More »
Endo International PLC has finalized the divestiture of Litha Healthcare Group to Acino Pharma AG. Read More »
Arena Pharmaceutical Inc. has completed Phase 1 of its comparative bioavailability study on pharmacokinetic profile of extended release ralinepag in comparison to immediate release. Read More »
Meridian Bioscience Inc. released comments on a recent Food and Drug Administration Safety Notification concerning Magellan Diagnostics. Read More »
Baxter International Inc. and Tel Aviv University through Ramot have entered a new licensing agreement that will be assessing technologies that are being developed at the university and Tel Aviv Sourasky Medical Center. Read More »
KaloBios Pharmaceuticals Inc. of California, specializing in rare and neglected diseases, recently obtained FDA clearance for its oral anti-parasitic medication benznidazole designed to combat Chagas disease, a tropical malady transmitted to humans by insects. Read More »
Progressive women's health care company Agile Therapeutics Inc. of Princeton, New Jersey has resubmitted its Twirla hormonal contraceptive patch to the U.S. Food and Drug Administration for a New Drug Application. Read More »
Pfizer Inc. and Merck released positive data from two Phase 3 studies of ertugliflozin, an investigational oral GGLT-2 inhibitor that seeks to treat Type 2 diabetes patients by improving glycemic control. Read More »
Novo Nordisk is recalling insulin cartridge holders of the NovoPen Echo model, warning that they may crack if they are in the presence of chemicals, such as those found in cleaners. Read More »
Cardiome Pharma Corp. partner SteadyMed Ltd. has submitted a New Drug Application for Trevyent with the U.S. Food and Drug Administration. Read More »
Pediatric-onset hypophosphatasia, an extremely rare metabolic disease affecting bone structure and strength, came into sharper focus recently when Alexion Pharmaceuticals won funding for its Strensiq medication from two sources via a managed access agreement. Read More »
Alerts Sign-up
